AVCNF (Avicanna) EV-to-Revenue : 1.53 (As of Dec. 15, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Avicanna EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Avicanna's enterprise value is $28.10 Mil. Avicanna's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $18.37 Mil. Therefore, Avicanna's EV-to-Revenue for today is 1.53.

The historical rank and industry rank for Avicanna's EV-to-Revenue or its related term are showing as below:

AVCNF' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.23 Med: 9.33 Max: 1494.68
Current: 1.61

During the past 8 years, the highest EV-to-Revenue of Avicanna was 1494.68. The lowest was 1.23. And the median was 9.33.

AVCNF's EV-to-Revenue is ranked better than
65.69% of 994 companies
in the Drug Manufacturers industry
Industry Median: 2.495 vs AVCNF: 1.61

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-12-15), Avicanna's stock price is $0.2709. Avicanna's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.19. Therefore, Avicanna's PS Ratio for today is 1.40.

Avicanna EV-to-Revenue Historical Data

The historical data trend for Avicanna's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna EV-to-Revenue Chart

Avicanna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

387.64

34.59

13.21

9.04

2.45

Avicanna Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EV-to-Revenue	Get a 7-Day Free Trial															3.85	2.45	2.60	1.97	1.91

Competitive Comparison of Avicanna's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Avicanna's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avicanna's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avicanna's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Avicanna's EV-to-Revenue falls into.

Avicanna EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Avicanna's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	28.101	/	18.374
	=	1.53

Avicanna's current Enterprise Value is $28.10 Mil.
Avicanna's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.37 Mil.

Avicanna (OTCPK:AVCNF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Avicanna's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.2709	/	0.194
	=	1.40

Avicanna's share price for today is $0.2709.
Avicanna's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.19.

Avicanna EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Avicanna's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Avicanna Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (OTCPK:AVCNF) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

0NN:Germany AVCN:Canada

Address

480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2

Website

https://www.avicanna.com

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.